8-K: Cadrenal Therapeutics CFO Departs, CEO Takes Interim Role

Cadrenal Therapeutics announced the departure of its Chief Financial Officer, Matthew K. Szot, with CEO Quang X. Pham assuming interim CFO duties.

Summary

• Matthew K. Szot has transitioned from his role as Chief Financial Officer of Cadrenal Therapeutics, Inc., effective May 28, 2026.
• Quang X. Pham, the current Chief Executive Officer, has been appointed as the interim Chief Financial Officer and interim Principal Accounting Officer.
• The company is actively searching for a permanent replacement for the CFO position.
• A separation and release agreement was entered into with Mr. Szot on June 3, 2026.
• Under the agreement, Mr. Szot will receive severance payments totaling $365,806.00, paid in four installments.
• He will also receive his fiscal 2026 target cash bonus of $237,903.00, paid in two installments.
• All of Mr. Szot's outstanding stock options will have accelerated vesting.
• The agreement includes a general release of claims by Mr. Szot against the company and its affiliates.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive transition with a clear separation agreement, rather than a significant positive or negative development for the company's operations.

Positives

• The company has secured a separation agreement with its CFO, providing a clear path forward.
• The CEO stepping in as interim CFO demonstrates leadership commitment during the transition.
• Mr. Szot's stock options will be fully vested, allowing him to exercise them.
• The severance package and bonus payment provide financial support to the departing CFO.
• The agreement includes a mutual release of claims, aiming to prevent future disputes.

Negatives

• The departure of a CFO can signal internal challenges or strategic shifts.
• The company is incurring significant severance costs: $365,806 in severance and $237,903 in bonus.
• The need to search for a new CFO indicates a vacancy in a critical financial leadership role.

Risks

• The company is undergoing a CFO transition, which could impact financial planning and investor confidence.
• The severance agreement is subject to a seven-day revocation period, meaning it may not be immediately effective.
• The company's ability to attract and retain a qualified CFO could be a challenge.

Future Outlook

The company is actively searching for a permanent Chief Financial Officer. No specific guidance or forward-looking financial projections are provided in this filing.

Management Comments

• Quang X. Pham, Chief Executive Officer, has assumed the interim role of Chief Financial Officer and Principal Accounting Officer.
• The company is in the process of conducting a search for Mr. Szot's replacement.

Industry Context

StockSavvy.ai notes that CFO transitions are common in the life sciences sector, particularly for companies navigating clinical development or seeking further funding. The appointment of the CEO as interim CFO is a pragmatic step to ensure continuity.

Management Changes

Stakeholder Impact

• Shareholders: The departure of a CFO and the subsequent search for a replacement may create short-term uncertainty, but the clear separation agreement and interim leadership aim to mitigate disruption.
• Employees: The transition may lead to a period of adjustment in financial reporting and operations, but the CEO's interim role provides continuity.
• Creditors: The company's financial obligations related to the severance package are clearly defined, providing transparency to creditors.

Next Steps

• Cadrenal Therapeutics will continue its search for a permanent Chief Financial Officer.
• Matthew K. Szot will receive severance payments and his bonus in scheduled installments.
• Matthew K. Szot's stock options will remain exercisable until their original expiration date.

Key Dates

Keywords

CFO Departure, Interim CFO, Separation Agreement, Severance Package, Cadrenal Therapeutics, Executive Transition, Stock Options, Form 8-K